Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 18;36(3):817-825.
doi: 10.1093/humrep/deaa298.

Birthweight and other perinatal outcomes of singletons conceived after assisted reproduction compared to natural conceived singletons in couples with unexplained subfertility: follow-up of two randomized clinical trials

Collaborators, Affiliations

Birthweight and other perinatal outcomes of singletons conceived after assisted reproduction compared to natural conceived singletons in couples with unexplained subfertility: follow-up of two randomized clinical trials

J A Wessel et al. Hum Reprod. .

Abstract

Study question: Does assisted reproduction, such as ovarian stimulation and/or laboratory procedures, have impact on perinatal outcomes of singleton live births compared to natural conception in couples with unexplained subfertility?

Summary answer: Compared to natural conception, singletons born after intrauterine insemination with ovarian stimulation (IUI-OS) had a lower birthweight, while singletons born after IVF had comparable birthweights, in couples with unexplained subfertility.

What is known already: Singletons conceived by assisted reproduction have different perinatal outcomes such as low birthweight and a higher risk of premature birth than naturally conceived singletons. This might be due to the assisted reproduction, such as laboratory procedures or the ovarian stimulation, or to an intrinsic factor in couples with subfertility.

Study design, size, duration: We performed a prospective cohort study using the follow-up data of two randomized clinical trials performed in couples with unexplained subfertility. We evaluated perinatal outcomes of 472 live birth singletons conceived after assisted reproduction or after natural conception within the time horizon of the studies.

Participants/materials, setting, methods: To assess the possible impact of ovarian stimulation we compared the singletons conceived after IUI with FSH or clomiphene citrate (CC) and IVF in a modified natural cycle (IVF-MNC) or standard IVF with single embryo transfer (IVF-SET) to naturally conceived singletons in the same cohorts. To further look into the possible effect of the laboratory procedures, we put both IUI and IVF groups together into IUI-OS and IVF and compared both to singletons born after natural conception. We only included singletons conceived after fresh embryo transfers. The main outcome was birthweight presented as absolute weight in grams and gestational age- and gender-adjusted percentiles. We calculated differences in birthweight using regression analyses adjusted for maternal age, BMI, smoking, parity, duration of subfertility and child gender.

Main results and the role of chance: In total, there were 472 live birth singletons. Of the 472 singleton pregnancies, 209 were conceived after IUI-OS (136 with FSH and 73 with CC as ovarian stimulation), 138 after IVF (50 after IVF-MNC and 88 after IVF-SET) and 125 were conceived naturally.Singletons conceived following IUI-FSH and IUI-CC both had lower birthweights compared to naturally conceived singletons (adjusted difference IUI-FSH -156.3 g, 95% CI -287.9 to -24.7; IUI-CC -160.3 g, 95% CI -316.7 to -3.8). When we compared IVF-MNC and IVF-SET to naturally conceived singletons, no significant difference was found (adjusted difference IVF-MNC 75.8 g, 95% CI -102.0 to 253.7; IVF-SET -10.6 g, 95% CI -159.2 to 138.1). The mean birthweight percentile was only significantly lower in the IUI-FSH group (-7.0 percentile, 95% CI -13.9 to -0.2). The IUI-CC and IVF-SET group had a lower mean percentile and the IVF-MNC group a higher mean percentile, but these groups were not significant different compared to the naturally conceived group (IUI-CC -5.1 percentile, 95% CI -13.3 to 3.0; IVF-MNC 4.4 percentile, 95% CI -4.9 to 13.6; IVF-SET -1.3 percentile, 95% CI -9.1 to 6.4).Looking at the laboratory process that took place, singletons conceived following IUI-OS had lower birthweights than naturally conceived singletons (adjusted difference -157.7 g, 95% CI -277.4 to -38.0). The IVF group had comparable birthweights with the naturally conceived group (adjusted difference 20.9 g, 95% CI -110.8 to 152.6). The mean birthweight percentile was significantly lower in the IUI-OS group compared to the natural group (-6.4 percentile, 95% CI -12.6 to -0.1). The IVF group was comparable (0.7 percentile, 95% CI -6.1 to 7.6).

Limitations, reasons for caution: The results are limited by the number of cases. The data were collected prospectively alongside the randomized controlled trials, but analyzed as treated.

Wider implications of the findings: Our data suggest IUI in a stimulated cycle may have a negative impact on the birthweight of the child and possibly on pre-eclampsia. Further research should look into the effect of different methods of ovarian stimulation on placenta pathology and pre-eclampsia in couples with unexplained subfertility using naturally conceived singletons in the unexplained population as a reference.

Study funding/competing interest(s): Both initial trials were supported by a grant from ZonMW, the Dutch Organization for Health Research and Development (INeS 120620027, SUPER 80-83600-98-10192). The INeS study also had a grant from Zorgverzekeraars Nederland, the Dutch association of healthcare insurers (09-003). B.W.J.M. is supported by an NHMRC investigator Grant (GNT1176437) and reports consultancy for ObsEva, Merck Merck KGaA, Guerbet and iGenomix, outside the submitted work. A.H. reports grants from Ferring Pharmaceutical company (the Netherlands), outside the submitted work. F.J.M.B. receives monetary compensation as a member of the external advisory board for Merck Serono (the Netherlands), Ferring Pharmaceutics BV (the Netherlands) and Gedeon Richter (Belgium), he receives personal fees from educational activities for Ferring BV (the Netherlands) and for advisory and consultancy work for Roche and he receives research support grants from Merck Serono and Ferring Pharmaceutics BV, outside the submitted work. The remaining authors have nothing to disclose.

Trial registration number: INeS study Trial NL915 (NTR939); SUPER Trial NL3895 (NTR4057).

Keywords: birthweight; laboratory procedures; ovarian stimulation; perinatal outcomes; unexplained subfertility.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study flowchart. IUI-CC, intrauterine insemination with clomiphene citrate; IUI-FSH, intrauterine insemination with follicle stimulating hormone; IUI-OS, intrauterine insemination with ovarian stimulation; IVF-MNC, IVF in a modified natural cycle; IVF-SET, standard IVF with single embryo transfer.

Similar articles

  • Expectant management versus IUI in unexplained subfertility and a poor pregnancy prognosis (EXIUI study): a randomized controlled trial.
    Wessel JA, Mochtar MH, Besselink DE, Betjes H, de Bruin JP, Cantineau AEP, Groenewoud ER, Hooker AB, Lambalk CB, Kwee J, Kaaijk EM, Louwé LA, Maas JWM, Mol BWJ, van Rumste MME, Traas MAF, Goddijn M, van Wely M, Mol F. Wessel JA, et al. Hum Reprod. 2022 Nov 24;37(12):2808-2816. doi: 10.1093/humrep/deac236. Hum Reprod. 2022. PMID: 36331493 Free PMC article. Clinical Trial.
  • Is IVF-served two different ways-more cost-effective than IUI with controlled ovarian hyperstimulation?
    Tjon-Kon-Fat RI, Bensdorp AJ, Bossuyt PM, Koks C, Oosterhuis GJ, Hoek A, Hompes P, Broekmans FJ, Verhoeve HR, de Bruin JP, van Golde R, Repping S, Cohlen BJ, Lambers MD, van Bommel PF, Slappendel E, Perquin D, Smeenk J, Pelinck MJ, Gianotten J, Hoozemans DA, Maas JW, Groen H, Eijkemans MJ, van der Veen F, Mol BW, van Wely M. Tjon-Kon-Fat RI, et al. Hum Reprod. 2015 Oct;30(10):2331-9. doi: 10.1093/humrep/dev193. Epub 2015 Aug 12. Hum Reprod. 2015. PMID: 26269539 Clinical Trial.
  • Endometrial scratching in women with one failed IVF/ICSI cycle-outcomes of a randomised controlled trial (SCRaTCH).
    van Hoogenhuijze NE, Mol F, Laven JSE, Groenewoud ER, Traas MAF, Janssen CAH, Teklenburg G, de Bruin JP, van Oppenraaij RHF, Maas JWM, Moll E, Fleischer K, van Hooff MHA, de Koning CH, Cantineau AEP, Lambalk CB, Verberg M, van Heusden AM, Manger AP, van Rumste MME, van der Voet LF, Pieterse QD, Visser J, Brinkhuis EA, den Hartog JE, Glas MW, Klijn NF, van der Meer S, Bandell ML, Boxmeer JC, van Disseldorp J, Smeenk J, van Wely M, Eijkemans MJC, Torrance HL, Broekmans FJM. van Hoogenhuijze NE, et al. Hum Reprod. 2021 Jan 1;36(1):87-98. doi: 10.1093/humrep/deaa268. Hum Reprod. 2021. PMID: 33289528 Free PMC article. Clinical Trial.
  • Top 10 priorities for future infertility research: an international consensus development study.
    Duffy JMN, Adamson GD, Benson E, Bhattacharya S, Bhattacharya S, Bofill M, Brian K, Collura B, Curtis C, Evers JLH, Farquharson RG, Fincham A, Franik S, Giudice LC, Glanville E, Hickey M, Horne AW, Hull ML, Johnson NP, Jordan V, Khalaf Y, Knijnenburg JML, Legro RS, Lensen S, MacKenzie J, Mavrelos D, Mol BW, Morbeck DE, Nagels H, Ng EHY, Niederberger C, Otter AS, Puscasiu L, Rautakallio-Hokkanen S, Sadler L, Sarris I, Showell M, Stewart J, Strandell A, Strawbridge C, Vail A, van Wely M, Vercoe M, Vuong NL, Wang AY, Wang R, Wilkinson J, Wong K, Wong TY, Farquhar CM; Priority Setting Partnership for Infertility. Duffy JMN, et al. Fertil Steril. 2021 Jan;115(1):180-190. doi: 10.1016/j.fertnstert.2020.11.014. Epub 2020 Nov 30. Fertil Steril. 2021. PMID: 33272617
  • Age-related natural fertility outcomes in women over 35 years: a systematic review and individual participant data meta-analysis.
    Chua SJ, Danhof NA, Mochtar MH, van Wely M, McLernon DJ, Custers I, Lee E, Dreyer K, Cahill DJ, Gillett WR, Righarts A, Strandell A, Rantsi T, Schmidt L, Eijkemans MJC, Mol BWJ, van Eekelen R. Chua SJ, et al. Hum Reprod. 2020 Aug 1;35(8):1808-1820. doi: 10.1093/humrep/deaa129. Hum Reprod. 2020. PMID: 32696041

Cited by

References

    1. Bensdorp AJ, Tjon-Kon-Fat RI, Bossuyt PM, Koks CA, Oosterhuis GJ, Hoek A, Hompes PG, Broekmans FJ, Verhoeve HR, de Bruin JP. et al. Prevention of multiple pregnancies in couples with unexplained or mild male subfertility: randomised controlled trial of in vitro fertilisation with single embryo transfer or in vitro fertilisation in modified natural cycle compared with intrauterine insemination with controlled ovarian hyperstimulation. BMJ 2015;350:g7771. - PMC - PubMed
    1. Berntsen S, Soderstrom-Anttila V, Wennerholm UB, Laivuori H, Loft A, Oldereid NB, Romundstad LB, Bergh C, Pinborg A.. The health of children conceived by ART: ‘the chicken or the egg?’. Hum Reprod Update 2019;25:137–158. - PubMed
    1. Chen XK, Wen SW, Bottomley J, Smith GN, Leader A, Walker MC.. In vitro fertilization is associated with an increased risk for preeclampsia. Hypertens Pregnancy 2009;28:1–12. - PubMed
    1. Danhof NA, van Wely M, Repping S, Koks C, Verhoeve HR, de Bruin JP, Verberg MFG, van Hooff MHA, Cohlen BJ, van Heteren CF. et al.; SUPER Study Group. Follicle stimulating hormone versus clomiphene citrate in intrauterine insemination for unexplained subfertility: a randomized controlled trial. Hum Reprod 2018;33:1866–1874. - PubMed
    1. De Geyter C, Calhaz-Jorge C, Kupka MS, Wyns C, Mocanu E, Motrenko T, Scaravelli G, Smeenk J, Vidakovic S, Goossens V. et al. ART in Europe, 2014: results generated from European registries by ESHRE: the European IVF-monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). Hum Reprod 2018;33:1586–1601. - PubMed

Publication types